Trump Strikes Deal To Slash Cost Of Obesity Drugs To As Low As $150 A Month

Written By Guest User

President Trump is continuing his crusade against high U.S. drug prices — this time targeting what he calls the “fat drug.” He announced deals Thursday meant to bring down costs of some obesity medicines to as little as $149 per month and expand access to more Medicare enrollees.

BY THE NUMBERS
Under the agreement, drugs like Wegovy and Zepbound will be made available for eligible patients at around $350 per month, down from as much as $1,350, the White House said. The copay for patients enrolled in Medicare will be as low as $50. In addition, new oral versions — still awaiting approval — could cost as little as $149 per month.

  • ”Eli Lilly and Novo Nordisk are committing to offer Zepbound and Wegovy at most-favored-nations rates for American patients,” Trump said. It follows similar deals he’s made with Pfizer, AstraZeneca, and EMD Serono to bring down the cost of other drugs.

  • Americans will be able to buy some GLP-1 drugs through Trump’s direct-to-consumer website, TrumpRx.gov, which is set to launch in January 2026. Americans are expected to pay $350 per monthly dose there, and that price is expected to be lowered to $245 within two years.

About 12% of Americans report having taken a GLP-1 drug. Trump mentioned that several members of his Cabinet, and Communications Director Steven Cheung, were taking them.

Guest User
Previous

FAA To Cut Thousands Of Flights At 40 Major U.S. Airports
Next

Average First-Time American Homebuyer Is Now 40 Years Old